Overview

The aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).

Eligibility

Inclusion Criteria:

• Age : 6 - 18 years old.
• All children diagnosed by Primary monosymptomatic nocturnal enuresis in this age group.

Exclusion Criteria:

• Secondary nocturnal enuresis (child who has been continent for at least 6 months before the onset of bedwetting ).
• congenital anomalies (Posterior urethral valve , ectopic ureter , ectopia vesica ,…)
• history of previous lower urinary tract surgery (Multiple hypospadias surgeries ,…, )
• neurogenic bladder (as underactive bladder ).and urge incontinence.
• presence of post-void residual urine greater than 20% of functional bladder capacity.
• history or evidence of disorders in other organs such as (cardiovascular system disease), liver , psychological problems , evident allergic reaction to both medication.